GlaxoSmithKline bucks downward trend in stock market after reporting positive drug trial results
Shares of GSK, the former GlaxoSmithKline, extended this year’s rally after positive drug trial results improved the company’s sales prospects, a bright spot in a US stock market that’s teetering in bear market territory.
GSK Plc (GSK), formerly known as GlaxoSmithKline, was among the few bright spots in a sea of red that has engulfed the US stock market after a report that inflation hit another four-decade high. GSK’s American depositary shares (ADS) gained 1.5%, bucking the trend that has seen the S&P 500 index slump 2.7% by midday, after the London-based company announced positive results for its vaccine candidate for respiratory syncytial virus (RSV).
The pharmaceutical company plans to seek regulatory approval for its first RSV vaccine in the second half of the year for the drug that it expects to reduce the 360,000 hospitalisations and more than 24,000 deaths worldwide each year from the infectious disease, Hal Barron, GSK’s Chief Scientific Officer, said. The phase 3 drug trial covered adults aged 60 years and older. Regulatory approval for the company’s vaccine candidate may help boost sales prospects for a company that has held on to gains this year, rising 8.5% in New York even as the S&P 500 index has teetered on the brink of a bear market.
Is GSK still a buy, or is it time to cash in on gains and sell?
Only seven of 21 analysts who cover the stock rated it as a “buy”, while one says investors need to add more to their holdings, according to Wall Street Journal. Twelve of them have a “hold” recommendation on the stock, and one has “sell.” On average, analysts expect the company’s US shares to rise to $45.64, representing less than a 5% upside for the stock that traded at $43.51 on Friday. “We expect revenue to continue being supported by its new and specialty products and vaccines,” Wan Nurhayati, an equity analyst at CFRA said in a note dated June 4, days before the latest drug trial results were released. CFRA had a “hold” recommendation on the stock and a target price of $44 then.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.